Objective: Visfatin, a novel adipokine originally discovered as a pre-B-cell colony enhancing factor, is expressed by amniotic epithelium, cytotrophoblast, and decidua and is over-expressed when fetal membranes are exposed to mechanical stress and/or pro-inflammatory stimuli. Visfatin expression by fetal membranes is dramatically up-regulated after normal spontaneous labor. The aims of this study were to determine if visfatin is detectable in amniotic fluid (AF) and whether its concentration changes with gestational age, spontaneous labor, preterm prelabor rupture of membranes (preterm PROM) and in the presence of microbial invasion of the amniotic cavity (MIAC). Methods: In this cross-sectional study, visfatin concentration in AF was determined in patients in the following groups: 1) mid-trimester (ns75); 2) term not in labor (ns27); 3) term in spontaneous labor (ns51); 4) patients with preterm labor with intact membranes (PTL) without MIAC who delivered at term (ns35); 5) patients with PTL without MIAC who delivered preterm (ns52); 6) patients with PTL with MIAC (ns25); 7) women with preterm PROM without MIAC (ns26); and 8) women with preterm PROM with MIAC (ns26). Non-parametric statistics were used for analysis. Results: 1) The median AF concentration of visfatin was significantly higher in patients at term than in midtrimester; 2) Among women with PTL who delivered preterm, the median visfatin concentration was significantly higher in patients with MIAC than those without MIAC; 3) Similarly, patients with PTL and MIAC had a higher median AF visfatin concentration than those with PTL who delivered at term; 4) Among women with preterm PROM, the median AF visfatin concentration was significantly higher in patients with MIAC than those without MIAC. Conclusions: 1) Visfatin is a physiologic constituent of AF; 2) The concentration of AF visfatin increases with advancing gestational age; 3) AF visfatin concentration is elevated in patients with MIAC, regardless of the membrane status, suggesting that visfatin participates in the host response against infection.
Introduction
Spontaneous preterm parturition is syndromic in nature w107, 112x, and several mechanisms of disease have been implicated in the pathogenesis of this condition, including intrauterine infection/inflammation w11, 37, 40, 65, 80, 86, 112, 115x, uteroplacental ischemia w4, 60, 61, 70, 83, 131x, uterine overdistention w9, 50, 68, 99x , allergic reactions w13x, cervical insufficiency w106x, hormonal disorders w19x and other mechanisms which have eluded identification. Infection is the only pathological process for which a causal relationship with preterm labor has been established w52, 110x.
There is compelling evidence that cytokines play a central role in the mechanism of infection-induced preterm labor w16, 38, 41, 44, 52, 56, 78, 81, 108, 109, 115, 132x . Interleukin (IL)-1 and tumor necrosis factor (TNF)-a are produced by human decidua in response to stimuli by bacterial products w14, 113, 116x, and stimulate prostaglandin production by amnion and decidua w105, 115x. TNF-a can stimulate the production of matrix metalloproteinases (MMPs) w32, 133x which have been implicated in membrane rupture w5, 76, 104x and cervical ripening w95, 100, 133x. In addition, amniotic fluid concentrations of immunoreactive IL-1 and TNF-a are elevated in women with preterm labor in the presence of infection w103, 111x. Moreover, IL-1 can stimulate myometrial contractions w121x and administration of this cytokine can induce preterm labor and preterm birth in pregnant animals w114x. In addition to IL-1 w114, 116x and TNF-a w14, 28, 29, 32, 113, 115, 133x , other cytokines have been implicated in the mechanisms of disease in preterm labor, including IL-6 w3, 23, 42, 51, 102x, IL-16 w6x, IL-18 w97x, granulocyte colony-stimulating factor w39, 122x, and macrophage migration inhibitory factor w15x. Consistent with these findings, expression of the antiinflammatory cytokine IL-10 was decreased in the placenta of pregnancies complicated by chorioamnionitis w49x.
Visfatin is a 52 kDa cytokine that has been identified as a growth factor for early B cells, termed pre-B cell colony-enhancing factor (PBEF) w123x. More than a decade later, it was re-discovered as an adipokine w54, 126, 128x which is highly expressed in visceral fat. Visfatin is also constitutively expressed in the myometrium w25x, placenta w74x, and all layers of human fetal membranes w92x. Its gene is up-regulated in the fetal membranes in response to mechanical stretch and term or preterm labor w88, 92x. Parturition also causes increased gene expression from the myometrium w25x, as well as the membranes, resulting in an increase in its protein in maternal serum w25, 120x.
Visfatin gene expression is increased in a number of inflammatory conditions including: acute lung injury w136x, colon cancer w53x, sepsis w55x, psoriasis w62x, metabolic syndrome w30, 31x, and rheumatoid arthritis w90x. In addition, gene expression of visfatin/PBEF is increased in chorioamnionitis w91x. Subsequent in vitro experiments have shown that the inflammatory mediators, LPS, TNFa, IL-6, and IL-1b up-regulate visfatin in the fetal membranes w92x and the up-regulation of its gene following IL-1b stimulation is modulated by the classic pro-inflammatory transcription factor NF-kB and AP-1 w57x.
Although visfatin lacks a conventional secretion sequence its secretion from human amniotic epithelial cells w93x, lymphocytes w123x, neutrophils w55x, and adipocytes w125, 128x has been demonstrated. Currently, its mechanism of secretion is unknown w128x; however, its exogenous application to explants of fetal membrane causes a number of pro-inflammatory modulators (i.e., TNF-a, IL-6, IL-1b, and IL-8) and enzymes (i.e., pro-MMP-1, -3, COX-2) to increase w94x. Furthermore, visfatin is anti-apoptotic for both amniotic epithelial and mesenchymal cells w58, 92x and neutrophils w55x. Collectively, these findings suggest that visfatin plays a role in the inflammatory process, in regulation of other proinflammatory cytokines, and in the preservation of immune cells.
The aims of this study were to determine if visfatin is detectable in amniotic fluid (AF) and whether its concentration changes with gestational age, spontaneous labor at term, in preterm prelabor rupture of membranes (preterm PROM), and in the presence of microbial invasion of the amniotic cavity (MIAC).
Materials and methods

Study design and population
A cross-sectional study was conducted by searching our clinical database and bank of biological samples. This study included women divided into eight groups: 1) mid-trimester (ns75); 2) term not in labor (ns27); 3) term in spontaneous labor (ns51); 4) patients with preterm labor with intact membranes (PTL) without MIAC who delivered at term (ns35); 5) patients with PTL without MIAC who delivered preterm (ns52); 6) patients with PTL with MIAC (ns25); 7) women with preterm PROM without MIAC (ns26); and 8) women with preterm PROM with MIAC (ns26).
The indications for transabdominal amniocentesis in patients from groups 2-8 were the detection of MIAC and/or assessment of fetal lung maturity. A sample of amniotic fluid was transported to the laboratory in a sterile capped syringe for culture of aerobic/anaerobic bacteria and genital Mycoplasmas. Amniotic fluid white blood cell (WBC) count, glucose concentrations and Gram stain were also performed. The results of these tests were used for subsequent clinical management. Amniotic fluid not required for clinical purposes was centrifuged at 48C for 10 min to remove cellular and particulate matter, and stored at -708C. Patients in the mid-trimester did not have tests for the detection of inflammation/infection because the indication for amniocentesis was karyotype analysis.
Definitions
The inclusion criteria for normal pregnancy (groups 1, 2 and 3) were: (1) no medical, obstetrical or surgical complications; (2) absence of MIAC; (3) intact membranes at the time of amniocentesis; and (4) delivery of a term neonate (G37 weeks) with a birthweight above the 10 th percentile w2, 43x. Preterm labor was defined as the presence of regular uterine contractions occurring at a frequency of at least two every 10 min, associated with 
Human visfatin C-terminal immunoassay
Concentrations of visfatin in amniotic fluid were determined using a specific and sensitive enzyme immunoassay (Phoenix Pharmaceuticals Inc., Belmont, CA). Visfatin C-terminal assays were validated in our laboratory for use with human amniotic fluid prior to the conduction of this study. Validation included spike and recovery experiments, which produced parallel curves indicating that amniotic fluid matrix constituents did not interfere with the antigen-antibody binding in this assay system. Visfatin enzyme immunoassays are based on the principle of competitive binding and were conducted according to recommendations of the manufacturer. Briefly, assay plates were pre-coated with a secondary antibody and the non-specific binding sites were blocked. Standards and samples were incubated in the assay plates along with primary antiserum and biotinylated peptide. The secondary antibody in the assay plates bound to the Fc fragment of the primary antibody whose Fab fragment competitively bound with both the biotinylated peptide and peptide standard or targeted peptide in the samples. Following incubation, the assay plates were repeatedly washed to remove unbound materials and incubated with a streptavidin-horseradish peroxidase (SA-HRP) solution. Then, unbound enzyme conjugate was removed by repeated washing and a substrate solution was added to the wells of the assay plates. Color developed in proportion to the amount of biotinylated peptide-SA-HRP complex but inversely proportional to the amount of peptide in the standard solutions or the samples. Color development was stopped with the addition of an acid solution and the intensity of color was read using a programmable spectrophotometer (SpectraMax M2, Molecular Devices, Sunnyvale, CA). Amniotic fluid concentrations of visfatin C were determined by interpolation from individual standard curves composed of human visfatin peptide. The calculated inter-and intra-assay coefficients of variation for Visfatin C-terminal immunoassays in our laboratory were 5.2% and 2.3%, respectively. The lower limit of detection (sensitivity) was calculated to be 0.04 ng/mL.
Statistical analysis
Shapiro-Wilk and Kolmogorov-Smirnov tests were used to test for normal distribution of the data. Data are presented as mean"SD for normally distributed parameters and as median (range) for those which were not normally distributed. Non-parametric methods were used to perform the statistical analysis for parameters which were not normally distributed, such as amniotic fluid visfatin concentration. Comparisons between groups for continuous variables were performed using the Kruskal-Wallis test with post hoc analysis (Mann-Whitney U-test). The Chisquare or Fisher's exact tests were used for categorical variables. Comparisons among groups for normally distributed parameters were performed using one-way ANOVA with Bonferroni adjustment for the calculated P-value in order to maintain the significance level at 0.05. Correlation between amniotic fluid concentrations of visfatin and gestational age, amniotic fluid WBC count and amniotic glucose concentration was conducted with Spearman's rank correlation. A P-value of 0.05 was considered statistically significant. The statistical package used was SPSS v.14.0 (SPSS Inc., Chicago, IL, USA).
Results
Tables 1 and 2 display the clinical and obstetrical characteristics of the study groups. There was no significant difference in the gestational age at sampling between women at term in labor and those at term not in labor. Values are expressed as median (minimum-maximum) or as mean"SD. MIAC -microbial invasion of the amniotic cavity; NS -not significant. Similarly, the gestational age at sampling was comparable between the three groups of patients with PTL as well as between women with preterm PROM. Visfatin was detectable in all amniotic fluid samples.
Amniotic fluid visfatin concentrations in mid-trimester and in term gestations
The median amniotic fluid concentration of visfatin was significantly higher in patients at term not in labor, than in those in the mid-trimester of pregnancy (median: 89.6 ng/mL, range: 12.7-250.4 vs. 9.2 ng/mL 4.9-85.7, respectively; P-0.001) (Figure 1) . Among women at term, there was no significant difference in the median amniotic fluid visfatin concentration between those with and without labor (term in labor: 57.7 ng/mL 4.9-176.7 vs. term not in labor 89.6 ng/mL, 12.7-250.4, P)0.05).
Amniotic fluid visfatin concentrations in spontaneous preterm labor and intact membranes
Among women with PTL and intact membranes, the median amniotic fluid visfatin concentration was significantly higher in patients with MIAC than in those who delivered at term without MIAC (83.4 ng/mL, 18.3-316.8 vs. 47.1 ng/mL, 4.9-118.8 ng/mL, respectively; P-0.001). Similarly, the median amniotic fluid visfatin concentration was significantly higher in patients with MIAC than in those who delivered preterm without MIAC (83.4 ng/mL, 18.3-316.8 vs. 52.9 ng/mL, 5.3-316.8, respectively; Ps0.006) (Figure 2 ). Among women with preterm labor without MIAC, no significant difference was found in the median amniotic fluid concentration of visfatin between women who delivered at term and those who delivered preterm (Figure 2 ).
Amniotic fluid visfatin concentrations in preterm PROM
Among women with preterm PROM, the median amniotic fluid visfatin concentration was significantly higher in patients with MIAC than in those without MIAC (60.5 ng/mL, 10.2-289.9 vs. 31.7 ng/mL, 4.9-124.3, respectively; Ps0.01) (Figure 3 ). Among patients with MIAC there was no significant difference in the median amniotic fluid concentration of visfatin between women with PTL with intact membranes and those with preterm PROM. Similarly, among patients without MIAC there was no significant difference in the median amniotic fluid concentration of visfatin between women with PTL with intact membranes who delivered preterm and those with preterm PROM.
Amniotic fluid visfatin concentrations were negatively correlated with both amniotic fluid glucose concentration (rs-0.21, Ps0.002), and the amniocentesis-to-delivery interval (rs-0.29, Ps0.001). Amniotic fluid visfatin concentrations were positively correlated with both amniotic fluid WBC count (rs0.48, Ps0.001) and gestational age at amniocentesis in women with normal pregnancy (rs0.69, P-0.001).
Discussion
Principal findings of the study 1) Immunoreactive visfatin is a physiologic constituent of the amniotic fluid; 2) the median amniotic fluid concentration of visfatin increase with advancing gestational age; 3) among women with spontaneous PTL and intact membranes, those with MIAC had a significantly higher median amniotic fluid visfatin concentration compared to those without MIAC who delivered either at term or preterm; 4) similarly, in patients with preterm PROM, the median amniotic fluid visfatin concentration was significantly higher in women with MIAC as compared to those without MIAC; 5) amniotic fluid visfatin concentrations were negatively correlated with amniotic fluid glucose concentrations and with amniocentesis-to-delivery interval; and 6) amniotic fluid visfatin concentrations were positively correlated with the amniotic fluid WBC count.
Visfatin, a novel adipokine and an ancient inflammatory mediator
Visfatin is a novel adipokine w8, 22, 33, 48, 126x that has been previously identified as a growth factor for early B cells, termed pre-B cell colony-enhancing factor (PBEF) w55, 74, 92, 123, 136x. Its gene, mapped on the long arm of chromosome 7 (7q22) w91x, has only one large open reading frame which encodes a polypeptide of 473 amino acids with an estimated molecular weight of 52 kDa w123x. The expression of visfatin/PBEF has been reported in mammals w20, 74, 77, 89, 91-94, 123, 129, 130, 136x as well as in fish w34x, invertebrates w85x and bacteria w73x. Its high conservation suggests that visfatin/PBEF probably plays an important biological role. In humans, visfatin is produced by visceral adipose tissue w54, 126x. Nevertheless, it is also expressed in large amounts in bone marrow, liver, muscle w123, 126x, heart, lung, kidney, placenta w123x, monocytes and neutrophils w55x.
What is the physiological role of visfatin?
While the specific physiological role of visfatin has not been completely elucidated, there is evidence to suggest that visfatin has at least three major features: immunoregulatory, metabolic, and intracellular phosphoribosyl tranferase activity.
Evidence in support that visfatin has immunoregulatory properties include: 1) It synergizes with IL-7 and stem cell factor to promote the growth of B cell precursors w123x; 2) visfatin up-regulates the production of pro-and antiinflammatory cytokines (e.g., IL-1b, IL-6, IL-10, and TNF-a) in human monocytes w84, 92x; 3) visfatin mRNA expression is up-regulated in neutrophils harvested from septic, critically ill patients w55x. It is also expressed w55, 87, 127, 135x, synthesized, and released w55x by neutrophils in response to inflammatory stimuli and contributes to prolonged neutrophil survival in clinical sepsis w55x; 4) nuclear factor-kB (NF-kB) and AP-1, members of the transcription factor family, have been implicated in the up-regulation of pro-inflammatory cytokines and the amplification and perpetuation of the inflammatory response w59, 64, 82x. Both have been reported to mediate the up-regulation of PBEF gene in human amniotic epithelial cells culture after an inflammatory stimulus w57x, and visfatin induces NF-kB transcriptional activity in human endothelial cells w1x. Furthermore, the genomic organization of the gene coding for visfatin revealed a NF-kB binding element in the third intron w91x; 5) gene expression of this adipokine is increased in lung tissue of animals with acute lung injury w35, 36, 136x; 6) polymorphisms in the gene for visfatin are associated with both increased and decreased risk for acute respiratory distress syndrome w7, 69x; and 7) patients with inflammatory bowel disease, a chronic inflammatory condition, have an elevated serum visfatin concentration as well as an increased expression of visfatin mRNA in intestinal epithelium w84x. Similarly, plasma w96x and synovial fluid w90x concentrations of visfatin are higher in patients with rheumatoid arthritis than in healthy controls.
The evidence for the metabolic effects of visfatin include: 1) visfatin-deficient mice have an impaired glucose tolerance and a decrease in insulin secretion after glucose injection than in control animals w101x; 2) in vitro exposure to glucose results in an increase in its secretion by adipocytes w47x; 3) visfatin exhibits insulin mimetic properties w54, 134x; 4) administration of glucose to human subjects is associated with elevation in circulating visfatin w47x; 5) a visfatin promoter polymorphism is associated with increased risk for Type-2 diabetes mellitus w69, 137x; 6) patients with Type-2 diabetes mellitus have a higher plasma visfatin concentration than non-diabetic subjects w21, 24, 27, 46, 67, 124x; 7) visfatin serum concentrations are higher in patients with gestational diabetes mellitus (GDM) than in normal pregnant women w63, 66x. Of note, plasma visfatin concentrations in the first trimester predict insulin sensitivity during the second trimester w75x, and a positive correlation between fasting glucose and visfatin concentrations was reported in normal pregnant women and in those with GDM w45x; and 8) circulating concentration of visfatin correlates with quantity of intra-visceral fat as estimated by computed tomography w124x as well as with BMI w8, 18, 124x and waist circumference w30x.
Visfatin is also an intracellular phosphoribosyl transferase that is involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD) via the salvage pathway. NAD is an important coenzyme for the regulation of numerous metabolic pathways and for several NAD dependent deacetylases. This enzymatic action of visfatin has been confirmed from its bacterial w73x and murine homologues w119x.
Visfatin is a physiological component of the amniotic fluid
This is the first study reporting the presence of visfatin in amniotic fluid. Visfatin was detectable in the amniotic fluid of all patients included in this study, from the early second trimester until 42 weeks of gestation, suggesting that visfatin is a physiologic component of human amniotic fluid. Moreover, visfatin concentrations increased with advancing gestational age, as indicated by its positive correlation with gestational age at amniocentesis.
The source of this protein in the amniotic fluid is currently unknown. Several studies have reported the detection of visfatin in the maternal circulation w17, 26, 63, 66, 71x. In accordance with the increased amniotic fluid visfatin concentrations during pregnancy reported herein, maternal serum visfatin concentration also increases with advancing gestation w75x. In addition, visfatin is expressed in the myometrium w25x and decidua w92x. Circulating visfatin is also detectable in cord blood w10, 71, 72x, where its concentration correlates with birth weight percentile w10, 72x.
The placenta was one of the first organs reported as a tissue in which visfatin is expressed w123x. Subsequently, several studies have demonstrated gene expression of visfatin in amniotic cell culture w57, 58, 74, 89, 91x. Visfatin was immunolocalized in the amniotic epithelium, mesenchymal cells of the amniotic connective tissue, chorionic cytotrophoblast and parietal decidua w74, 89, 91-94x. Importantly, in vitro studies have demonstrated that amniotic cells secrete visfatin w58, 93x. In the study reported herein, visfatin was detectable in the amniotic fluid in normal pregnancy as early as the beginning of the second trimester. This finding is consistent with the earliest expression of visfatin in fetal membranes reported at 13 weeks of gestation w92x.
Amniotic fluid visfatin concentration increases with advancing gestation
The findings that the median amniotic fluid concentration of visfatin was significantly higher at term than in midgestation, and was positively correlated with gestational age at amniocentesis are novel. Fetal membranes secrete this cytokine w58, 92, 93x and acute or chronic mechanical stretching of the fetal membranes is associated with increased expression and secretion of visfatin w58, 88, 89x. The chorioamniotic membranes are distended by 40% at 25-29 weeks of gestation, 60% at 30-34 weeks of gestation, and 70% or more at term w12, 79, 98x. The increase in the median concentration of amniotic fluid visfatin with advancing gestation and the positive correlation with gestational age support the aforementioned reports regarding the association between fetal membranes stretching and increased expression and secretion of visfatin. In addition, visfatin has anti-apoptotic properties, and can exert its effect on amniotic epithelial cells w58x, fibroblasts w93x and neutrophils w55x. It is tempting to postulate that the physiological increase of visfatin in amniotic fluid with advancing pregnancy aims to protect the fetal membranes from apoptosis and thus, prevent preterm PROM. Alternatively, given the unique combination of immunoregulatory and anti-apoptotic properties of visfatin, it can be argued that its concentration increases in the presence of MIAC as a defense mechanism against the inflammatory process or to help sustain neutrophils in the amniotic fluid.
Amniotic fluid visfatin concentration increases in the presence of infection
Patients with MIAC had a higher median amniotic fluid concentration of visfatin compared to those with a negative amniotic fluid culture, regardless of the membrane status. Indeed, this is the first in vivo study demonstrating an association between visfatin and infection in humans. Moreover, visfatin concentration correlated with wellestablished indices of intra-amniotic inflammation such as amniotic fluid glucose concentrations (rs-0.21, Ps0.002) and WBC count (rs0.48, Ps0.001). These parameters are being routinely used to diagnose intraamniotic inflammation w117, 118x. Finally, amniotic fluid visfatin concentrations were negatively correlated with the amniocentesis-to-delivery interval (rs-0.29, Ps0.001). Collectively, these new findings may point to a regulatory role of visfatin in the inflammatory response to acute infection.
The cross-sectional nature of this study does not allow us to discern a cause and effect relationship between amniotic fluid visfatin and infection; however, our hypothesis regarding the role of visfatin in intra-amniotic infection is supported by the following findings: 1) visfatin can exert an anti-apoptotic effect on neutrophils, amniotic epithelial cells and fibroblasts w55, 58, 93x; thus, it may protect fetal membranes as well as neutrophils in amniotic fluid against apoptosis induced by infection or labor. Indeed, it is possible that the higher median visfatin concentration in patients with MIAC than those without intraamniotic infection is the result of secretion from neutrophils into the amniotic fluid; 2) exposure of cultured amniotic cells to lipopolysaccharide stimulates the secretion of visfatin, and treatment with an antisense oligonucleotide to visfatin obliterate its secretion w93x; 3) several inflammatory mediators, such as IL-6, IL-1b and TNF-a have been shown to significantly increase the expression of visfatin in amniotic epithelial cells w91x. Furthermore, in vitro, visfatin induces a dose-dependent increase in the expression of IL-6 in amniotic epithelial cells and fetal membranes w92x; Noteworthy, IL-6, TNFa, IL-1 and IL-8 have been implicated in intra-amniotic infection w3, 14, 23, 28, 29, 32, 42, 51, 102, 103, 111, 113-116, 133x; 4) visfatin induces, in a dose-dependent manner, the expression and secretion of IL-8, a potent chemotactic agent; 5) results of microarray studies reveal that the visfatin gene is up-regulated during labor (an inflammatory state) in myometrium w25x and fetal membranes w94x. Consistent with the findings of the present study, visfatin gene expression is higher in fetal membranes taken from patients with preterm labor and infection compared to those without infection w74, 91x.
In conclusion, this is the first in vivo study describing the presence of visfatin in amniotic fluid and its association with acute infection in humans. While the physiological roles of visfatin are undoubtedly complex and need further study, the findings of the present report suggest that visfatin has a role in normal gestation, as well as in the inflammatory response associated with infection. Thus, increased secretion of this protein from fetal membranes, and possibly from intra-amniotic leukocytes in the presence of infection, may be an attempt to protect the epithelial cells from apoptosis. The anti-apoptotic effect of visfatin on epithelial cells may have clinical implications. Intra-amniotic administration of visfatin, or therapeutic manipulation of its concentrations, may help to prevent preterm PROM. The potential of therapeutic intervention may be of special benefit to patients with high risk for preterm PROM, such as those with multiple gestations and over distended uterus.
